Rchr
J-GLOBAL ID：201801008209312904   Update date: Apr. 26, 2024

Ayumi Taguchi

Ayumi Taguchi
Research field  (1)： Obstetrics and gynecology
Research theme for competitive and other funds  (8)：
  • 2022 - 2025 HPV感染細胞の免疫回避とT細胞免疫応答に着目したCIN予後予測法の確立
  • 2021 - 2024 卵巣明細胞癌におけるがん関連血栓症発症メカニズムの解明
  • 2021 - 2024 Genomic profiling and drug screening among organoids derived from ovarian cancer patients
  • 2020 - 2023 Multimodal analysis of chromatin 3D structure using deep learning in gynecological malignancies
  • 2020 - 2023 子宮頸部胃型腺癌におけるオルガノイド培養の確立と治療方法の開発
Show all
Papers (132)：
  • Futaba Inoue, Kenbun Sone, Kohei Kumegawa, Ryuta Hachijo, Eri Suzuki, Saki Tanimoto, Natsumi Tsuboyama, Kosuke Kato, Yusuke Toyohara, Yu Takahashi, et al. Inhibition of protein arginine methyltransferase 6 activates interferon signaling and induces the apoptosis of endometrial cancer cells via histone modification. International journal of oncology. 2024. 64. 3
  • Osamu Kobayashi, Ayumi Taguchi, Takahiro Nakajima, Yuji Ikeda, Keisuke Saito, Kei Kawana. Immunotherapy that leverages HPV-specific immune responses for precancer lesions of cervical cancer. Taiwanese Journal of Obstetrics and Gynecology. 2024. 63. 1. 22-28
  • Yusuke Toyohara, Kenbun Sone, Katsuhiko Noda, Kaname Yoshida, Shimpei Kato, Masafumi Kaiume, Ayumi Taguchi, Ryo Kurokawa, Yutaka Osuga. The automatic diagnosis artificial intelligence system for preoperative magnetic resonance imaging of uterine sarcoma. Journal of Gynecologic Oncology. 2024. 35
  • Yusuke Toyohara, Ayumi Taguchi, Yoshiyuki Ishii, Daisuke Yoshimoto, Miki Yamazaki, Hiroko Matsunaga, Kazuma Nakatani, Daisuke Hoshi, Saki Tsuchimochi, Misako Kusakabe, et al. Identification of target cells of human papillomavirus 18 using squamocolumnar junction organoids. Cancer science. 2023
  • Ayumi Taguchi, Kosuke Kato, Konan Hara, Akiko Furusawa, Yujiro Nakajima, Chihiro Ishizawa, Michihiro Tanikawa, Kenbun Sone, Mayuyo Mori, Muneaki Shimada, et al. Heterogeneous treatment effects of adjuvant therapy for patients with cervical cancer in the intermediate-risk group. Cancer Medicine. 2023
ｍore...
MISC (98)：
ｍore...
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM